semaglutide cvd Weight-loss drug tied to lower risk of death from COVID, heart disease, all causes SELECT: Semaglutide's Impact on CVD

2023;doi:10.1016/S0140-6736(23)01163-7

Rita Kapoor The medical community and patients alike have celebrated the arrival of GLP-1 receptor agonists, such as Ozempic and Wegovy , as groundbreaking tools for weight management and metabolic health

Share your diary with your doctor so they can help you choose the best foods

Maximum weight loss results are often achieved after several months of consistent use

A 2017 meta-analysis found no significant increase in pancreatitis or pancreatic cancer risks (odds ratios 0.93 and 0.94, respectively)

The GLP-1 group had a decline in total daily insulin use from 61.28 U at baseline to 56.13 U at 6 months